Malaria Information and Prophylaxis, by Country [A]

The information presented in this table is consistent 1 with the information in the CDC Health Information for International Travel (the “Yellow Book”).

  1. A
  2. B
  3. C
  4. D
  5. E
  6. F
  7. G
  8. H
  9. I
  10. J
  11. K
  12. L
  13. M
  14. N
  15. O
  16. P
  17. Q
  18. R
  19. S
  20. T
  21. U
  22. V
  23. W
  24. X
  25. Y
  26. Z
Malaria Information and Prophylaxis by Country 
Country Areas with Malaria Drug Resistance2 Malaria Species3 Recommended Chemoprophylaxis4 Key Information Needed and Helpful Links to Assess Need for Prophylaxis for Select Countries
Afghanistan April–December in all areas at altitudes below 2,500 m (8,202 ft). Chloroquine Primarily P. vivax .

Less commonly, P. falciparum

Atovaquone-proguanil, doxycycline, mefloquine, or tafenoquine5
Albania None Not Applicable Not Applicable Not Applicable
Algeria None Not Applicable Not Applicable Not Applicable
American Samoa (U.S.) None Not Applicable Not Applicable Not Applicable
Andorra None Not Applicable Not Applicable Not Applicable
Angola All Chloroquine Primarily P. falciparum.
Less commonly, P. malariae, P. ovale, or P. vivax
Atovaquone-proguanil, doxycycline, mefloquine, or tafenoquine5
Anguilla (U.K.) None Not Applicable Not Applicable Not Applicable
Antarctica None Not Applicable Not Applicable Not Applicable
Antigua and Barbuda None Not Applicable Not Applicable Not Applicable
Argentina None Not applicable Not applicable Not applicable
Armenia None Not Applicable Not Applicable Not Applicable
Aruba None Not Applicable Not Applicable Not Applicable
Australia None Not Applicable Not Applicable Not Applicable
Austria None Not Applicable Not Applicable Not Applicable
Azerbaijan None Not Applicable Not Applicable Not Applicable
Azores (Portugal) None Not Applicable Not Applicable Not Applicable

1. Factors that affect local malaria transmission patterns can change rapidly and from year to year, such as local weather conditions, mosquito vector density, and prevalence of infection. Information in these tables is updated regularly.
2.  Refers to P. falciparum malaria unless otherwise noted.
3. Estimates of malaria species are based on best available data from multiple sources. Where proportions are not available, the primary species and less common species are identified.
4. Several medications are available for chemoprophylaxis. When deciding which drug to use, consider specific itinerary, length of trip, cost of drug, previous adverse reactions to antimalarials, drug allergies, and current medical history. All travelers should seek medical attention in the event of fever during or after return from travel to areas with malaria.
5. Primaquine and tafenoquine can cause hemolytic anemia in persons with glucose-6-phosphate dehydrogenase (G6PD) deficiency. Before prescribing primaquine or tafenoquine, patients must be screened for G6PD deficiency using a quantitative test.
6. Mosquito avoidance includes applying topical mosquito repellant, sleeping under an insecticide treated bed net, and wearing protective clothing (e.g., long pants and socks, long sleeve shirt). For additional details on mosquito avoidance, see: https://www.cdc.gov/malaria/travelers/index.html
7. P. knowlesi is a malaria species with a simian host (macaque). Human cases have been reported from most countries in Southeast Asia and are associated with activities in forest or forest-fringe areas. This species of malaria has no known resistance to antimalarials.

Page last reviewed: November 2, 2021